study on the ef ficacy of recombinant hepatitis b vaccine in iranian infants

in order to determine the efficacy of recombinant hepatitis b vaccine in iranian infants, we analyzed the efficacy of a recombinant hepatitis b vaccine in 115 infants aged 12-24 months born to hbsag negative mothers who received three doses of hbv antibody to hepatitis b surface antigen (anti-hbs) was checked after the third dose of the vaccine, 94.8% of the infants had developed protective antibody levels. the vaccine was well-tolerated and no serious adverse effects were reported. this study is in agreement with a who report which recommends that the easiest and most cost-effective strategy for the control and eventual eradication of hbv would be to immunize all newborns with hepatitis b vaccine only [world health organization report, 1984].